| Autor: |
Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A., Miller, T.P. |
| Zdroj: |
Annals of Oncology; January 1994, Vol. 5 Issue: 1, Number 1 Supplement 2 pS91-S95, 5p |
| Abstrakt: |
CHOP is a four-drug, first-generation combination chemotherapy regimen that has cured approximately 30% of all patients with advanced stages of intermediate- or high-grade non-Hodgkin's lymphoma in national cooperative group trials. Initial single-institution studies of third-generation regimens such as m-BACOD, ProMACE-CytaBOM, and MACOP-B suggested that 55%-60% of these patients might be cured. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
